BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 28, 2026
Home » Blogs » BioWorld MedTech Perspectives » Public accusations and paranoia at FDA

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Public accusations and paranoia at FDA

March 16, 2015
By Mark McCarty

200px-Food_and_Drug_Administration_logo.svgAs those in attendance at ACC 2015 know, Jeff Popma of Beth Israel Deaconess asked publicly whether the 30-day data for Sapien 3 should suffice for approval of the device, but the story grew more interesting today (March 16). I was at a session at ACC dealing with translation of research into clinical practice, and Bram Zuckerman, director of the cardiovascular devices division at FDA’s Office of Device Evaluation, was on the dais. He talked a little about how FDA approaches evidence and so on, and really had little to say that he hasn’t said many times before.

Someone in the audience asked Zuckerman about whether the U.S. premarket review system should not look more like the system at work in Europe, and I followed with a question about whether an approval of Sapien 3 and other TAVR devices would be as a PMA supplement or as a PMA, and whether he could characterize his conversations with industry about PMA supplements for TAVR generally.

That didn’t sit well with Zuckerman, who said “this question is designed to obtain confidential information” about a device application. He went so far as to say that my presence was “an example of the kinds of people” who attend events like ACC 2015, and I suppose I should have been flattered when he described me as “a well-known member” of the press.

I wasn’t aware I am all that well known. After all, Medical Device Daily is a small-volume publication. If you want someone who is well known, try tracking down a name with the New York Times. They’re well known, but I doubt seriously whether more than 1,000 people in this world know who I am.

In any event, Zuckerman’s allegation that I was looking for confidential information is absurd. I asked for some idea of the conversations between FDA and industry on the notion of what might constitute a reasonable set of conditions for the use of a PMA supplement for TAVR. Zuckerman’s confusion about whether I was asking about Sapien 3 specifically is understandable, but he could have just said he couldn’t answer the question due to confidentiality.

That wasn’t good enough, though. He decided to go out of his way in an attempt to embarrass me. For the record, I was embarrassed alright, but not for myself. I found Zuckerman’s paranoia odd, not to mention unbecoming of his self-described status as a “humble public servant.”

I get that everyone has a bad day now and then, but this was way out of line. Bram Zuckerman needs to realize that the media have their place in this world. If he doesn’t like dealing with questions, maybe he should get a job that keeps him safe and sound in a place where no one has the temerity to challenge his authority. Until that day arrives, he might want to consider that it’s not the job of those in government to attempt to bully the press.

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of cancer cell in crosshairs being destroyed

    RX-10616 improves radiotherapy efficacy in HNSCC

    BioWorld Science
    Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing